Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

GSK (LSE: GSK) in 2026: Oncology Breakout, HIV Power and the Vaccines Question UK Investors Are Watching

After the consumer healthBusinesswas demerged as Haleon, GSK pitched itself to investors as a more focused biopharma company with deeper exposure to fast-growing therapy areas. The 2025 prints provide some of the strongest evidence to date that this strategy is bearing fruit, particularly in …

Ankur Sharma | 15 May 2026

Why Did LSE:NCYT - Novacyt Shares Collapse Today Amid FTSE AIM Healthcare Volatility?

Why Is LSE:NCYT - Novacyt Falling Sharply Today Despite Healthcare Sector Interest?

Ankur Sharma | 14 May 2026

Is LSE:THAT - Thalia Therapeutics Benefiting From the Global Healthcare and Biotech Recovery Trade?

Why Is LSE:THAT - Thalia Therapeutics Becoming a Trending UK Healthcare Stock in May 2026?

Ankur Sharma | 14 May 2026

Could LSE:SPI - Spire Healthcare Become The Biggest UK Healthcare Takeover Story Of 2026?

LSE:SPI shares exploded higher on May 14 2026 after the company confirmed it had received a potential £1 billion takeover proposal from Toscafund Asset Management, one of its largest shareholders. The non-binding proposal offered 250p per share, representing a massive premium to the prior …

Ankur Sharma | 14 May 2026

Could LSE:OPTI - OptiBiotix Health Benefit From Rising Global Demand For Weight Loss And Microbiome Healthcare Products?

OptiBiotix Health shares moved sharply higher on 14 May 2026 as investors rotated back into speculative UK healthcare growth stocks, particularly companies exposed to preventive healthcare, weight management, microbiome science, probiotics, nutraceutical innovation, and wellness products. The strong rally also reflects improving sentiment across …

Ankur Sharma | 14 May 2026

Is Biotech Weakness Hurting FAB Stock?

Fusion Antibodies PLC(LSE:FAB) has moved lower today as investor sentiment weakens across small-cap biotechnology and life sciences companies. Early-stage biotech businesses remain highly sensitive to funding conditions, commercial progress, and broader risk appetite within healthcare markets. This cautious environment is weighing on LSE:FAB.

Divya Sood | 14 May 2026

What Are the Key Risks Behind AGY’s Decline?

Allergy Therapeutics Plc(LSE:AGY) has moved lower today as investor sentiment weakens across biotechnology and specialty pharmaceutical companies. Small-cap healthcare businesses remain vulnerable to marketVolatility, regulatory uncertainty, and funding concerns. This cautious market environment is weighing on LSE:AGY.

Divya Sood | 14 May 2026

Can Ondine Biomedical Expand Across Global Healthcare Systems?

Ondine Biomedical, Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection technology. The company’s flagship product, Steriwave®, is designed to reduce harmful pathogens in the nasal passages without contributing to antimicrobial resistance (AMR). Ondine has increasingly attracted …

Ishan Mudgal | 14 May 2026

Is Poolbeg Pharma PLC a Promising Long-Term Healthcare Investment?

Poolbeg Pharma PLCis a clinical-stage biopharmaceutical company focused on developing innovative therapies for infectious diseases, cancer immunotherapy-related conditions, and metabolic disorders. The company has attracted growing investor interest due to its diversified pipeline, artificial intelligence-driven drug discovery platform, and advancement of POLB 001, its …

Ishan Mudgal | 14 May 2026

Is Poolbeg Pharma PLC a Promising Long-Term Healthcare Investment?

Poolbeg Pharma PLCis a clinical-stage biopharmaceutical company focused on developing innovative therapies for infectious diseases, cancer immunotherapy-related conditions, and metabolic disorders. The company has attracted growing investor interest due to its diversified pipeline, artificial intelligence-driven drug discovery platform, and advancement of POLB 001, its …

Ishan Mudgal | 14 May 2026
Support

Hi! How can we help you today?

Loading…